Who are COMIRNATY intramuscular injection's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): AntiCov-220, BNT162b2 Pfizer-BioNTech/Comirnaty, The Pfizer mRNA-based BNT162b2 vaccine, Ad26.COV2.S vaccine, COVAX only (1st and 2nd dose), Tozinameran (BNT162b2) / Riltozinameran (BNT162b2 OMI BA.1).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/comirnaty-intramuscular-injection.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

COMIRNATY intramuscular injection — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

COMIRNATY intramuscular injection (comirnaty-intramuscular-injection) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: mRNA vaccine.

marketed mRNA vaccine SARS-CoV-2 spike protein Live · refreshed every 30 min

Target snapshot

COMIRNATY intramuscular injection (comirnaty-intramuscular-injection) — Pfizer.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
COMIRNATY intramuscular injection TARGET	comirnaty-intramuscular-injection	Pfizer	marketed	mRNA vaccine	SARS-CoV-2 spike protein
AntiCov-220	AntiCov-220	Nguyen Thi Trieu, MD	marketed	Monoclonal antibody	SARS-CoV-2 spike protein
BNT162b2 Pfizer-BioNTech/Comirnaty	BNT162b2 Pfizer-BioNTech/Comirnaty	KK Women's and Children's Hospital	marketed	mRNA vaccine	SARS-CoV-2 spike protein (S protein)
The Pfizer mRNA-based BNT162b2 vaccine	The Pfizer mRNA-based BNT162b2 vaccine	dafna yahav	marketed	mRNA vaccine	SARS-CoV-2 spike protein (S protein)
Ad26.COV2.S vaccine	Ad26.COV2.S vaccine	University Medical Center Groningen	marketed	viral vector vaccine	SARS-CoV-2 spike protein
COVAX only (1st and 2nd dose)	COVAX only (1st and 2nd dose)	China National Biotec Group Company Limited	marketed	Inactivated viral vaccine	SARS-CoV-2 spike protein and other viral antigens
Tozinameran (BNT162b2) / Riltozinameran (BNT162b2 OMI BA.1)	tozinameran-bnt162b2-riltozinameran-bnt162b2-omi-ba-1	Pfizer	marketed	vaccine	SARS-CoV-2 spike protein

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (mRNA vaccine class)

Pfizer · 12 drugs in this class
ModernaTX, Inc. · 11 drugs in this class
BioNTech SE · 5 drugs in this class
Jules Bordet Institute · 5 drugs in this class
Tan Tock Seng Hospital · 2 drugs in this class
Clover Biopharmaceuticals AUS Pty · 1 drug in this class
CanSino Biologics Inc. · 1 drug in this class
Assistance Publique - Hôpitaux de Paris · 1 drug in this class
CSPC Megalith Biopharmaceutical Co.,Ltd. · 1 drug in this class
Jens D Lundgren, MD · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). COMIRNATY intramuscular injection — Competitive Intelligence Brief. https://druglandscape.com/ci/comirnaty-intramuscular-injection. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab